Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 3 and 1 respectively.
Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 3 and 1 respectively.
Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmonary Embolism - Overview
Pulmonary Embolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pulmonary Embolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pulmonary Embolism - Companies Involved in Therapeutics Development
Acticor Biotech SAS
Bio-Synectics Inc
China Resources Emde Biological Pharmaceutical Co Ltd
Indiana Lysis Technologies LLC
Kolmar Korea Co Ltd
Les Laboratoires Servier SAS
Supergene LLC
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Verseon Corp
Pulmonary Embolism - Drug Profiles
BS-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Pulmonary Embolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glenzocimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KKM-183A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reteplase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-62798 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Staphylokinase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-0023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
urokinase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-2851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zifa-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pulmonary Embolism - Dormant Projects
Pulmonary Embolism - Discontinued Products
Pulmonary Embolism - Product Development Milestones
Featured News & Press Releases
Oct 25, 2017: IU-based drug-discovery startup aims to use nanotechnology to digest blood clots in lungs
Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition
Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseons New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Pulmonary Embolism, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pulmonary Embolism - Pipeline by Acticor Biotech SAS, 2021
Pulmonary Embolism - Pipeline by Bio-Synectics Inc, 2021
Pulmonary Embolism - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, 2021
Pulmonary Embolism - Pipeline by Indiana Lysis Technologies LLC, 2021
Pulmonary Embolism - Pipeline by Kolmar Korea Co Ltd, 2021
Pulmonary Embolism - Pipeline by Les Laboratoires Servier SAS, 2021
Pulmonary Embolism - Pipeline by Supergene LLC, 2021
Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2021
Pulmonary Embolism - Pipeline by Techfields Pharma Co Ltd, 2021
Pulmonary Embolism - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2021
Pulmonary Embolism - Pipeline by Verseon Corp, 2021
Pulmonary Embolism - Dormant Projects, 2021
Pulmonary Embolism - Discontinued Products, 2021
List Of Figures
Number of Products under Development for Pulmonary Embolism, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
RELATED REPORTS
Pulmonary Arterial Hypertension (PAH) Market in China 2023
Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It occurs when the pulmonary
View ReportPulmonary Fibrosis - Global Clinical Trials Review, H2, 2021
Pulmonary Fibrosis - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Pulmonary Fibrosis - Global Clinical Trials Review, H2, 2021 provides an overview of Pulmonary Fibrosis Clinical trials scenario.
View ReportPulmonary Embolism - Pipeline Insight, 2021
DelveInsights, Pulmonary Embolism - Pipeline Insight, 2021, report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary Embolism pipeline landscape. It covers the pipeline drug profiles, including
View ReportVenous Thromboembolism (Cardiovascular) - Drugs in Development, 2021
Venous Thromboembolism (Cardiovascular) - Drugs in Development, 2021Venous Thromboembolism (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Venous Thromboembolism pipeline landscape.The report provides comprehensive information on the
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
